Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3110 participants.
Also called NCT05485961
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose supportive care
- Phase
- Phase 2/3
- Enrolled
- 3,110 participants
- Sponsor
- Registry
-
NCT05485961
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, France, Germany, Greece, Hong Kong SAR China, Hungary, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Norway, Poland, Portugal, Puerto Rico, Romania, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT05485961. Randomized; quadruple masking; primary purpose supportive care. Start 2024-04-27 (actual); primary completion 2029-05-22 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Acronym
- POSIBIL6ESKD
- Condition
- End Stage Kidney Disease
- Intervention (Drug)
- CSL300
- Intervention (Drug)
- Placebo
- Lead sponsor
- CSL Behring
Record details
- Record id
cardio:ct-nct05485961- Content hash
de423c8e78f1a189cbf6d1fd321eb974ee0af7cd147c64f9d915d7b2905fddca